Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dejan Bojanic

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Drug Discovery Today|December 12, 2001
Handbook of Drug ScreeningDejan Bojanic
Current Opinion in Pharmacology|September 25, 2009
Novel trends in high-throughput screeningLorenz M Mayr, Dejan Bojanic
Expert Opinion on Drug Metabolism & Toxicology|October 6, 2007
Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safetyJianling Wang, Laszlo Urban, Dejan Bojanic
Drug Discovery Today|October 26, 2005
Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug developmentSteven Whitebread, Jacques Hamon, Dejan Bojanic, et al.
Assay and Drug Development Technologies|September 18, 2008
Current trends in high-throughput screeningJohn Sterling, Dejan Bojanic, Richard M Eglen, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 28, 2006
High-throughput in vitro profiling assays: lessons learnt from experiences at NovartisBernard Faller, Jianling Wang, Alfred Zimmerlin, et al.
Journal of Biomolecular Screening|May 14, 2008
Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discoveryLeslie Bell, Shari Bickford, Phong Hung Nguyen, et al.
Journal of Biomolecular Screening|March 19, 2002
A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channelsDeborah F Baxter, Martin Kirk, Amy F Garcia, et al.
Journal of Biomolecular Screening|May 21, 2010
Assay development and screening of human DGAT1 inhibitors with an LC/MS-based assay: application of mass spectrometry for large-scale primary screeningJi-Hu Zhang, Thomas P Roddy, Pei-I Ho, et al.
Current Opinion in Drug Discovery & Development|April 23, 2008
Which aspects of HTS are empirically correlated with downstream success?Andreas Bender, Dejan Bojanic, John W Davies, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Drug Discovery Today|December 12, 2001
Handbook of Drug ScreeningDejan Bojanic
Current Opinion in Pharmacology|September 25, 2009
Novel trends in high-throughput screeningLorenz M Mayr, Dejan Bojanic
Expert Opinion on Drug Metabolism & Toxicology|October 6, 2007
Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safetyJianling Wang, Laszlo Urban, Dejan Bojanic
Drug Discovery Today|October 26, 2005
Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug developmentSteven Whitebread, Jacques Hamon, Dejan Bojanic, et al.
Assay and Drug Development Technologies|September 18, 2008
Current trends in high-throughput screeningJohn Sterling, Dejan Bojanic, Richard M Eglen, et al.
Expert Opinion on Drug Metabolism & Toxicology|November 28, 2006
High-throughput in vitro profiling assays: lessons learnt from experiences at NovartisBernard Faller, Jianling Wang, Alfred Zimmerlin, et al.
Journal of Biomolecular Screening|May 14, 2008
Evaluation of fluorescence- and mass spectrometry-based CYP inhibition assays for use in drug discoveryLeslie Bell, Shari Bickford, Phong Hung Nguyen, et al.
Journal of Biomolecular Screening|March 19, 2002
A novel membrane potential-sensitive fluorescent dye improves cell-based assays for ion channelsDeborah F Baxter, Martin Kirk, Amy F Garcia, et al.
Journal of Biomolecular Screening|May 21, 2010
Assay development and screening of human DGAT1 inhibitors with an LC/MS-based assay: application of mass spectrometry for large-scale primary screeningJi-Hu Zhang, Thomas P Roddy, Pei-I Ho, et al.
Current Opinion in Drug Discovery & Development|April 23, 2008
Which aspects of HTS are empirically correlated with downstream success?Andreas Bender, Dejan Bojanic, John W Davies, et al.
Pageof 2